CN1353573A - 对炎症介导感染的抗炎症治疗 - Google Patents

对炎症介导感染的抗炎症治疗 Download PDF

Info

Publication number
CN1353573A
CN1353573A CN00807547A CN00807547A CN1353573A CN 1353573 A CN1353573 A CN 1353573A CN 00807547 A CN00807547 A CN 00807547A CN 00807547 A CN00807547 A CN 00807547A CN 1353573 A CN1353573 A CN 1353573A
Authority
CN
China
Prior art keywords
inflammatory
virus
cell
agent
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00807547A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·安东尼
M·A·波莱斯
J·V·乔治
J·E·埃利奥特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CN1353573A publication Critical patent/CN1353573A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
CN00807547A 1999-05-14 2000-05-12 对炎症介导感染的抗炎症治疗 Pending CN1353573A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13409199P 1999-05-14 1999-05-14
US60/134,091 1999-05-14

Publications (1)

Publication Number Publication Date
CN1353573A true CN1353573A (zh) 2002-06-12

Family

ID=22461735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00807547A Pending CN1353573A (zh) 1999-05-14 2000-05-12 对炎症介导感染的抗炎症治疗

Country Status (13)

Country Link
EP (1) EP1202620A1 (ko)
JP (1) JP2002544210A (ko)
KR (1) KR20020024587A (ko)
CN (1) CN1353573A (ko)
AU (1) AU5010800A (ko)
BR (1) BR0010546A (ko)
CA (1) CA2368593A1 (ko)
HK (1) HK1047216A1 (ko)
IL (1) IL146130A0 (ko)
MX (1) MXPA01011606A (ko)
PL (1) PL351710A1 (ko)
TR (1) TR200103271T2 (ko)
WO (1) WO2000069255A1 (ko)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100488500C (zh) * 2000-07-20 2009-05-20 劳拉斯有限公司 Cox-2抑制剂预防免疫缺陷的用途
CN102002476A (zh) * 2010-08-20 2011-04-06 上海市公共卫生临床中心 一种体外培养人体黏膜活组织模型及其建立方法和应用
CN102557976A (zh) * 2010-12-15 2012-07-11 辽宁盛京制药有限公司 溴芬酸有机盐及其制备方法、其组合物及用途
CN105456273A (zh) * 2014-09-02 2016-04-06 杭州雷索药业有限公司 奈韦拉平在制备抗炎药物中的应用
CN106176739A (zh) * 2016-08-18 2016-12-07 滨州医学院 利托那韦增强糖皮质激素抗炎作用的医药新用途
CN106176751A (zh) * 2016-08-18 2016-12-07 滨州医学院 茚地那韦增强糖皮质激素抗炎作用的医药新用途
CN106309445A (zh) * 2016-08-18 2017-01-11 滨州医学院 奈非那韦增强糖皮质激素抗炎作用的医药新用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040072720A (ko) * 2002-01-10 2004-08-18 파마시아 앤드 업존 캄파니 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
ITMI20031311A1 (it) * 2003-06-27 2004-12-28 Indena Spa Formulazioni per il trattamento di disturbi artrosici.
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN104013959A (zh) * 2014-05-21 2014-09-03 郭和友 逆转录抑制剂和免疫抗体细胞三联合疗法
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
EP0407701A3 (en) * 1989-05-15 1992-04-22 Fujisawa Pharmaceutical Co., Ltd. Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100488500C (zh) * 2000-07-20 2009-05-20 劳拉斯有限公司 Cox-2抑制剂预防免疫缺陷的用途
CN102002476A (zh) * 2010-08-20 2011-04-06 上海市公共卫生临床中心 一种体外培养人体黏膜活组织模型及其建立方法和应用
CN102002476B (zh) * 2010-08-20 2013-05-08 上海市公共卫生临床中心 一种体外培养人体黏膜活组织模型及其建立方法和应用
CN102557976A (zh) * 2010-12-15 2012-07-11 辽宁盛京制药有限公司 溴芬酸有机盐及其制备方法、其组合物及用途
CN102557976B (zh) * 2010-12-15 2015-06-10 辽宁盛京制药有限公司 溴芬酸有机盐及其制备方法、其组合物及用途
CN105456273A (zh) * 2014-09-02 2016-04-06 杭州雷索药业有限公司 奈韦拉平在制备抗炎药物中的应用
CN106176739A (zh) * 2016-08-18 2016-12-07 滨州医学院 利托那韦增强糖皮质激素抗炎作用的医药新用途
CN106176751A (zh) * 2016-08-18 2016-12-07 滨州医学院 茚地那韦增强糖皮质激素抗炎作用的医药新用途
CN106309445A (zh) * 2016-08-18 2017-01-11 滨州医学院 奈非那韦增强糖皮质激素抗炎作用的医药新用途

Also Published As

Publication number Publication date
AU5010800A (en) 2000-12-05
JP2002544210A (ja) 2002-12-24
KR20020024587A (ko) 2002-03-30
EP1202620A1 (en) 2002-05-08
WO2000069255A1 (en) 2000-11-23
TR200103271T2 (tr) 2002-06-21
MXPA01011606A (es) 2003-09-10
IL146130A0 (en) 2002-07-25
HK1047216A1 (zh) 2003-02-14
CA2368593A1 (en) 2000-11-23
BR0010546A (pt) 2002-03-05
PL351710A1 (en) 2003-06-02
WO2000069255A8 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
CN1353573A (zh) 对炎症介导感染的抗炎症治疗
Vaughn et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease
Safadi et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes
Jansson et al. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice
Faunce et al. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis
Li et al. Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype
CN102505006B (zh) 干细胞和祖细胞分化的调节、鉴定及其应用
Veenbergen et al. Colonic tolerance develops in the iliac lymph nodes and can be established independent of CD103+ dendritic cells
Shacklett et al. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection
Kollmann et al. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1.
Lü et al. Oral mucosal immunity and HIV/SIV infection
US20100143305A1 (en) Treatment of hiv and aids using probiotic lactobacillus reuteri
US20030138399A1 (en) Anti-inflammatory therapy for inflammatory mediated infection
KR20220100913A (ko) Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법
Lv et al. Costunolide ameliorates colitis via specific inhibition of HIF1α/glycolysis-mediated Th17 differentiation
Katsanos et al. Impact of substance P on cellular immunity
Haroun et al. Chronic graft-versus-host disease in pediatric patients: differences and challenges
Teixeira-Carvalho et al. Cytokines, chemokine receptors, CD4+ CD25HIGH+ T-cells and clinical forms of human schistosomiasis
Horani et al. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis
Lee et al. Human immunodeficiency virus type 1 infection of mature CD3hiCD8+ thymocytes
Ekkens et al. Memory Th2 effector cells can develop in the absence of B7-1/B7-2, CD28 interactions, and effector Th cells after priming with an intestinal nematode parasite
Moniuszko et al. Decreased number of CD4+ and CD8+ T cells that express the interleukin-7 receptor in blood and tissues of SIV-infected macaques
Ruskoné-Fourmestraux et al. Gastrointestinal lymphoma: prevention and treatment of early lesions
JPH11246435A (ja) 免疫調整剤
de Paula Immunomodulatory Impact of Memory T Lymphocytes in Periodontitis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047216

Country of ref document: HK